Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression.

IF 15.1 1区 医学 Q1 PSYCHIATRY
American Journal of Psychiatry Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI:10.1176/appi.ajp.20230751
Matthew B Wall, Lysia Demetriou, Bruna Giribaldi, Leor Roseman, Natalie Ertl, David Erritzoe, David J Nutt, Robin L Carhart-Harris
{"title":"Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression.","authors":"Matthew B Wall, Lysia Demetriou, Bruna Giribaldi, Leor Roseman, Natalie Ertl, David Erritzoe, David J Nutt, Robin L Carhart-Harris","doi":"10.1176/appi.ajp.20230751","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Psilocybin is an emerging intervention for depression that may be at least as effective as selective serotonin reuptake inhibitors (SSRIs), but effects of the two treatments on the neural correlates of emotional processing have never been directly compared.</p><p><strong>Methods: </strong>The authors assessed neural responses to emotional faces using blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) in two groups with major depression. One group (N=25; 9 women and 16 men) received two dosing sessions with 25 mg psilocybin plus 6 weeks of daily inert placebo, and the second group (N=21; 6 women and 15 men) received 6 weeks of escitalopram plus two dosing sessions with a nonpsychoactive (placebo) dose of 1 mg psilocybin. Both groups had equal psychological support throughout: 3 hours of preparation, one in-person integration session following the psilocybin dosing sessions, and two further integration sessions conducted via video call or telephone. An emotional face fMRI paradigm was completed before treatment and at the 6-week posttreatment primary end point (3 weeks following psilocybin dosing sessions).</p><p><strong>Results: </strong>Patient group (psilocybin versus escitalopram) interacted with time point (before versus after treatment) on a distributed set of cortical regions. Post hoc within-condition analyses showed that posttreatment BOLD responses to emotional faces of all types were significantly reduced in the escitalopram group, with no change or a slight increase in the psilocybin group. Analyses of amygdala responsivity showed a reduction of response to fearful faces in the escitalopram group, but lesser effects for the psilocybin group.</p><p><strong>Conclusions: </strong>Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. These results are consistent with prior findings that the antidepressant action of SSRIs is often accompanied by a reduction in emotional responsiveness, but this effect may not occur in psychedelic therapy.</p>","PeriodicalId":7656,"journal":{"name":"American Journal of Psychiatry","volume":" ","pages":"569-582"},"PeriodicalIF":15.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1176/appi.ajp.20230751","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Psilocybin is an emerging intervention for depression that may be at least as effective as selective serotonin reuptake inhibitors (SSRIs), but effects of the two treatments on the neural correlates of emotional processing have never been directly compared.

Methods: The authors assessed neural responses to emotional faces using blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) in two groups with major depression. One group (N=25; 9 women and 16 men) received two dosing sessions with 25 mg psilocybin plus 6 weeks of daily inert placebo, and the second group (N=21; 6 women and 15 men) received 6 weeks of escitalopram plus two dosing sessions with a nonpsychoactive (placebo) dose of 1 mg psilocybin. Both groups had equal psychological support throughout: 3 hours of preparation, one in-person integration session following the psilocybin dosing sessions, and two further integration sessions conducted via video call or telephone. An emotional face fMRI paradigm was completed before treatment and at the 6-week posttreatment primary end point (3 weeks following psilocybin dosing sessions).

Results: Patient group (psilocybin versus escitalopram) interacted with time point (before versus after treatment) on a distributed set of cortical regions. Post hoc within-condition analyses showed that posttreatment BOLD responses to emotional faces of all types were significantly reduced in the escitalopram group, with no change or a slight increase in the psilocybin group. Analyses of amygdala responsivity showed a reduction of response to fearful faces in the escitalopram group, but lesser effects for the psilocybin group.

Conclusions: Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. These results are consistent with prior findings that the antidepressant action of SSRIs is often accompanied by a reduction in emotional responsiveness, but this effect may not occur in psychedelic therapy.

艾司西酞普兰而非裸盖菇素治疗抑郁症可降低大脑对情绪刺激的反应性。
目的:裸盖菇素是一种新兴的抑郁症干预措施,可能至少与选择性5 -羟色胺再摄取抑制剂(SSRIs)一样有效,但这两种治疗对情绪处理神经相关的影响从未被直接比较过。方法:作者使用血氧水平依赖(BOLD)功能磁共振成像(fMRI)评估两组重度抑郁症患者对情绪面孔的神经反应。一组(N=25;9名女性和16名男性)接受两次剂量治疗,25 mg裸盖菇素加6周每日惰性安慰剂,第二组(N=21;6名女性和15名男性)接受6周的艾司西酞普兰治疗,外加2次非精神活性(安慰剂)剂量1mg裸盖菇素。两组在整个过程中都有相同的心理支持:3小时的准备,一次裸盖菇素给药后的面对面整合,以及两次通过视频通话或电话进行的进一步整合。在治疗前和治疗后6周主要终点(裸盖菇素给药后3周)完成情绪面部功能磁共振成像范式。结果:患者组(裸盖菇素与艾司西酞普兰)与时间点(治疗前与治疗后)在一组分布的皮质区域上相互作用。事后条件内分析显示,艾司西酞普兰组治疗后对所有类型的情绪化面孔的BOLD反应显著降低,裸盖菇素组没有变化或略有增加。对杏仁核反应性的分析显示,艾司西酞普兰组对恐惧面孔的反应有所减少,但裸盖菇素组的影响较小。结论:尽管裸盖菇素组的抑郁症状有很大改善,但裸盖菇素治疗对大脑对情绪刺激的反应性只有很小的影响。这些结果与先前的发现一致,即SSRIs的抗抑郁作用通常伴随着情绪反应的降低,但这种效果可能不会发生在迷幻治疗中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Psychiatry
American Journal of Psychiatry 医学-精神病学
CiteScore
22.30
自引率
2.80%
发文量
157
审稿时长
4-8 weeks
期刊介绍: The American Journal of Psychiatry, dedicated to keeping psychiatry vibrant and relevant, publishes the latest advances in the diagnosis and treatment of mental illness. The journal covers the full spectrum of issues related to mental health diagnoses and treatment, presenting original articles on new developments in diagnosis, treatment, neuroscience, and patient populations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信